Schoeneck James A

Director Schoeneck buys 75.0K shares of CLDI at $2.00 amid 96.2% decline from 52-week high; 3-insider cluster buy in loss-making biotech.

Director James A Schoeneck purchased 75,000 shares at $2.00 on 2025-08-21, representing a 6613.8% increase in his holdings from 1,134 to 76,134 shares, while the stock trades at $1.56—96.2% below its 52-week high of $40.56. The transaction occurs within a cluster of 3 other insider purchases over the past 14 days, suggesting coordinated accumulation despite the company's unprofitable position (net income: $-5,715,000.00) and market-cap distress ($5,345,193.36). Schoeneck's historical cross-ticker track record shows 3 prior buys with average 90-day returns of +1390.0% and 100% win rate, though that pattern does not establish predictive power at this specific ticker. The confluence of severe equity collapse, unprofitability, multi-insider cluster activity, and a substantial position increase (from minimal to material) warrants examination of whether new information or restructuring dynamics underlie the coordinated buying.

Director Schoeneck James A bought 23,567 shares at $5.07; stock down 83.3% from 52-week high, but insider's prior FGEN trades delivered 90d returns of +2000.2% and +1933.4%.

Director Schoeneck James A purchased 23,567 shares at $5.07, increasing his holdings by 146.4% to 39,666 shares post-transaction in a heavily depressed stock (currently $5.25, -83.3% from 52-week high of $31.50). His cross-ticker track record across 2 prior buys shows an average 90d return of +1390.0% with a 100.00% win rate, and critically, his 2 prior purchases at FGEN on 2025-03-21 and 2025-03-20 each captured 90d returns exceeding +1900%, establishing a pattern of well-timed entry at this ticker. However, this purchase follows a 30-day and 90-day decline of -28.5% and -28.6% respectively, and the company's fundamentals have deteriorated: annual revenue growth is -80.0% and full-year net income was negative, though the latest quarter shows a reversal to $4.6M net income on $2.7M revenue. The concentration of prior buy expertise at this specific ticker (2 of 2 prior same-ticker trades were well-timed) contrasts sharply with the current macro weakness; investors should track whether this purchase represents a repeat of his earlier tactical entries or reflects material operational recovery obscured by recent price action.

Director Schoeneck purchases 300,000 shares for $105,040.00 at $0.35–$0.34, raising stake 406.9%, as stock drops 47.8% in 30 days from $66.00 peak.

James A. Schoeneck, a director at FibroGen, executed 2 separate purchases totaling 300,000 shares for $105,040.00 on 2025-03-20 and 2025-03-21, expanding his holdings from 73,722 to 373,722 shares. The purchases occurred at prices ($0.35 and $0.34) far below the 52-week high of $66.00, and in a sharp drawdown period: the stock is -47.8% over the past 30 days and -86.0% from its peak. The company is unprofitable with annual revenue declining -80.0% year-over-year and posted a quarterly net loss of $-17,084,000.00 against revenue of $46,333,000.00. This material acquisition by a director during severe price deterioration and operational stress suggests confidence in mean reversion or value at current levels, but it occurs amid fundamental distress that warrants scrutiny of the company's path to profitability.